Brief: Medical Marijuana, Inc. Major Investment Company Axim® Biotechnologies Files New U.S. Provisional Patent For Cannabis Gum As A Treatment For Migraine Symptoms
14/05/2019 14:13
May 14 (Reuters) - Axim Biotechnologies Inc AXIM.PK :
* MEDICAL MARIJUANA, INC. MAJOR INVESTMENT COMPANY AXIM®
BIOTECHNOLOGIES FILES NEW U.S. PROVISIONAL PATENT FOR CANNABIS
GUM AS A TREATMENT FOR MIGRAINE SYMPTOMS
Source text for Eikon: ID:nPn8vbhkda
Further company coverage: AXIM.PK
((Briefs@thomsonreuters.com;))
Recent news on Axim Biotechnologies
See all newsBrief: AXIM Biotechnologies Partners With Arizona State University To Determine Antibody Levels Against Covid-19
Brief: Axim Biotechnologies Inc Develops Next Generation Of Its Rapid Neutralizing Antibody Test For Covid-19
Brief: AXIM Biotechnologies To Acquire Technology Including
Brief: Axim® Biotechnologies Successfully Completes Point-Of-Care Clinical Trials On Its Rapid Covid-19 Neutralizing Antibody Test
Brief: Axim Biotechnologies Inc Says Filed A Provisional Patent For A First-In-Class Face Mask That Captures And Deactivates Sars-Cov-2